engleski

Expression of tumor-associated antigens MAGE, NY-ESO-1 and HER-2 in patients with relapsing invasive ductal breast cancer: an immunohistochemical study

By using monoclonal antibodies (mab) specific to HER-2 protein (Hercep Test DAKO, no. K5204), to MAGE family gene products (57B mab) (1) and to NY-ESO-1 (B9.8.1.1. mab) (2) an immunohistochemical analysis and comparison of the expression of these three antigens in cancer tissue in three groups of patients with invasive breast cancer was performed. All analyzed patients were treated at the University Hospital for Tumors, Zagreb, Croatia. 88 patients were studied. They were all operated, and had T1 to T3, N0 to N2, M0 tumors. As adjuvant therapy they all received postoperative irradiation and, if indicated, systemic therapy. In the majority of patients all these treatment modalities were performed in 1995. Regarding tumor relapse and the site of tumor relapse, based on the patients’ medical records from the Department of Radiation oncology after the minimum five years of the follow-up, these patients can be divided into three groups: a group without locoregional or bone metastases, a group with locoregional relapse, and a group with bone metastases. These three groups of patients were comparable in terms of tumor size, the number of involved axillary lymphnode metastases and tumor grade. Immunohistochemical analysis was performed on the patients’ archival paraffin embedded breast cancer tissues. MAGE antigen staining revealed a statistically significant difference in expression between the patients without locoregional relapse or bone metastases and the group with locoregional relapse (p=0.010). No significant difference was observed when these three groups of patients were compared for HER-2 or NY-ESO-1 expression. Obtained results confirm the observation (3) that the expression of MAGE gene products, detectable by routine immunohistochemical techniques on sentions could represent an important prognostic marker.

/

nije evidentirano